Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome
- PMID: 33721590
- DOI: 10.1016/j.ajem.2021.03.005
Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome
Abstract
Introduction: Case reports of immune checkpoint inhibitor (ICI) overlap syndrome of myasthenia gravis, myositis and myocarditis, are increasing in the published literature. This is a potentially fatal adverse event of ICIs and emergency physicians need to be familiar with this triad when patients present to the emergency department (ED).
Methods: We performed a retrospective chart review of the electronic medical record between September 1, 2016 to March 9, 2020. We identified patients with the overlap syndrome who presented to our ED.
Results: Seven patients were identified. Most were female and treated with a programmed cell death-1 inhibitor. Most patients presented with abnormal vital signs and the most common symptoms were ptosis, diplopia, dyspnea and fatigue. Most required supplemental oxygen and had a prolonged length of stay. All received steroids in addition to other immunomodulators. Two patients died.
Discussion: Presence of one of the diagnosis should lead to evaluation for the others. Suspicion should be raised by patients presenting with ptosis, muscular weakness, fatigue and dyspnea. Early recognition of this triad can allow for early administration of high-dose glucocorticoids (1-2 mg/kg of prednisone or equivalent), which is the mainstay of treatment. However, it is likely that patients will need further immunomodulators and therefore, will need hospitalization.
Conclusion: Emergency physicians should be aware of this potentially lethal triad in cancer patients receiving ICIs. The life-saving interventions in the ED include recognizing the triad, airway support, administration of high-dose glucocorticoids, and early involvement of a multidisciplinary team.
Keywords: Emergency department; Immune checkpoint inhibitor; Myasthenia gravis; Myocarditis; Myositis; irAE.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors.Arthritis Rheumatol. 2021 May;73(5):866-874. doi: 10.1002/art.41604. Epub 2021 Apr 1. Arthritis Rheumatol. 2021. PMID: 33258544
-
Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases.Oncologist. 2021 Dec;26(12):1052-1061. doi: 10.1002/onco.13931. Epub 2021 Aug 25. Oncologist. 2021. PMID: 34378270 Free PMC article.
-
Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation.Neuromuscul Disord. 2020 Jan;30(1):67-69. doi: 10.1016/j.nmd.2019.10.006. Epub 2019 Nov 4. Neuromuscul Disord. 2020. PMID: 31839404
-
Improved outcomes with early immunosuppression in patients with immune-checkpoint inhibitor induced myasthenia gravis, myocarditis and myositis: a case series.Support Care Cancer. 2023 Aug 12;31(9):518. doi: 10.1007/s00520-023-07987-x. Support Care Cancer. 2023. PMID: 37572133 Review.
-
Immune checkpoint inhibitors induced side effects of the peripheral nervous system.Curr Opin Neurol. 2023 Oct 1;36(5):427-431. doi: 10.1097/WCO.0000000000001188. Epub 2023 Jul 24. Curr Opin Neurol. 2023. PMID: 37639489 Review.
Cited by
-
Steroid-Refractory Myocarditis Induced by Immune Checkpoint Inhibitor Responded to Infliximab: Report of Two Cases and Literature Review.Cardiovasc Toxicol. 2024 Nov;24(11):1174-1191. doi: 10.1007/s12012-024-09918-6. Epub 2024 Sep 10. Cardiovasc Toxicol. 2024. PMID: 39256296 Free PMC article. Review.
-
Evaluation and management of acute high-grade immunotherapy-related neurotoxicity.Heliyon. 2023 Feb 14;9(3):e13725. doi: 10.1016/j.heliyon.2023.e13725. eCollection 2023 Mar. Heliyon. 2023. PMID: 36851967 Free PMC article. Review.
-
Myasthenia gravis, myositis and myocarditis: a fatal triad of immune-related adverse effect of immune checkpoint inhibitor treatment.BMJ Case Rep. 2022 Dec 8;15(12):e251966. doi: 10.1136/bcr-2022-251966. BMJ Case Rep. 2022. PMID: 36593626 Free PMC article.
-
TNF-α Inhibitors and Other Biologic Agents for the Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis.Front Immunol. 2022 Jul 1;13:922782. doi: 10.3389/fimmu.2022.922782. eCollection 2022. Front Immunol. 2022. PMID: 35844550 Free PMC article. Review.
-
Drugs That Induce or Cause Deterioration of Myasthenia Gravis: An Update.J Clin Med. 2021 Apr 6;10(7):1537. doi: 10.3390/jcm10071537. J Clin Med. 2021. PMID: 33917535 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical